3svh
From Proteopedia
(Difference between revisions)
(New page: '''Unreleased structure''' The entry 3svh is ON HOLD Authors: Filippakopoulos, P., Picaud, S., Felletar, I., Hewings, S.D., von Delft, F., Arrowsmith, C.H., Edwards, A.M., Weigelt, J., ...) |
|||
(6 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand== | |
+ | <StructureSection load='3svh' size='340' side='right'caption='[[3svh]], [[Resolution|resolution]] 1.80Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[3svh]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3SVH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3SVH FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.8Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=KRG:3-(3,5-DIMETHYL-1,2-OXAZOL-4-YL)-5-ETHOXYBENZOIC+ACID'>KRG</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3svh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3svh OCA], [https://pdbe.org/3svh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3svh RCSB], [https://www.ebi.ac.uk/pdbsum/3svh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3svh ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Disease == | ||
+ | [https://www.uniprot.org/uniprot/CBP_HUMAN CBP_HUMAN] Note=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with KAT6A; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with KAT6B. KAT6A-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:[https://omim.org/entry/180849 180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.<ref>PMID:11331617</ref> <ref>PMID:12114483</ref> <ref>PMID:12566391</ref> <ref>PMID:15706485</ref> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/CBP_HUMAN CBP_HUMAN] Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300.<ref>PMID:9707565</ref> <ref>PMID:11154691</ref> <ref>PMID:12738767</ref> <ref>PMID:12929931</ref> | ||
- | + | ==See Also== | |
- | + | *[[CREB-binding protein 3D structures|CREB-binding protein 3D structures]] | |
- | + | == References == | |
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Homo sapiens]] | ||
+ | [[Category: Large Structures]] | ||
+ | [[Category: Arrowsmith CH]] | ||
+ | [[Category: Bountra C]] | ||
+ | [[Category: Conway SJ]] | ||
+ | [[Category: Edwards AM]] | ||
+ | [[Category: Felletar I]] | ||
+ | [[Category: Filippakopoulos P]] | ||
+ | [[Category: Hewings SD]] | ||
+ | [[Category: Knapp S]] | ||
+ | [[Category: Picaud S]] | ||
+ | [[Category: Weigelt J]] | ||
+ | [[Category: Von Delft F]] |
Current revision
Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand
|
Categories: Homo sapiens | Large Structures | Arrowsmith CH | Bountra C | Conway SJ | Edwards AM | Felletar I | Filippakopoulos P | Hewings SD | Knapp S | Picaud S | Weigelt J | Von Delft F